In a move to further increase production efficiency and modernize the site, German contract development and manufacturing organization (CDMO) Rentschler Biopharma plans to construct a new buffer media station at its company headquarters in Laupheim. According to Rentschler, this is the largest single investment in the German site.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of cell and gene therapies, and Oxford-based mass photometry specialist Refeyn, to improve the manufacturing adeno-associated viruses (AAVs).
Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.
German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept. 14 it would end the arrangements with Germany’s Wacker Chemie and Switzerland’s Celonic Group, but leave the deals with Rentschler Biopharma and Novartis intact.
German CDMO Rentschler Biopharma is to establish manufacturing capacity for advanced therapy medicinal products (ATMPs), including Adeno-associated virus (AAV) vectors for clinical trials, at the Cell and Gene Therapy Catapult (CGT) site in Stevenage, UK.
German CDMO Rentschler Biopharma has reached agreement with Pfizer and BioNTech to handle the downstream purification process for the partnership’s mRNA-based COVID-19 vaccine. No price tag was disclosed for the deal that also calls for the CDMO to handle small-batch manufacturing for a range of BioNTech's other mRNA clinical-stage projects.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.
Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."
German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
Pharmaceutical Technology - The new manufacturing facility of German biotech company Rentschler has won the 2012 Facility of the Year Award (FOYA) in the category "Equipment Innovation" for its flexible, multi-product manufacturing facility designed to minimize manufacturing costs and product cycle times.
